Isolate Data
| Patient | Isolate | Region | Year | Species | Subtype | Source | Clone Method |
| CA1259 | CA3026 | U.S. | 1997 | HIV1 | B | Plasma | None |
Treatment History
| Order | Regimen | Weeks |
| 1 | AZT | 53 |
| 2 | AZT+DDC | 9 |
| 3 | D4T | 31 |
| 4 | 3TC+AZT | 42 |
| 5 | 3TC+AZT+IDV | 31 |
| 6 | 3TC+D4T+RTV+SQV | 34 |
RT Sequence
| NRTIMajorDRMs | NRTIMinorDRMs | NNRTIMajorDRMs | NNRTIMinorDRMs | Polys | UnusualMuts |
| M41L, D67N, M184V, L210W, T215Y | K219N | E44D, V118I, K122E, D123E, D177E, I178M, H208Y, R211K, E248D, A272P, K277X, T286A, E297K, A299X |
| >CA3026| codons 1-302 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALVEICTELEKDGKISKIGPENPYNTPV FAIKKKNSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSIPL DEEFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRKQNPEMVI YQYVDDLYVGSDLEIGQHRTKIEELRQYLWKWGFYTPDNKHQKEPPFLWMGYELHPDKWT VQPIVLPDKDSWTVNDIQKLVGKLNWASQIYPGIKVXQLCKLLRGAKALTEVIPLTKEXE LE |
Protease Sequence
| PIMajorDRMs | PIMinorDRMs | Polys | UnusualMuts |
| M46L, G48V, I54V, V82A | Q58E | L10I, L63C, A71V, V77I, Q92K, I93L |
| >CA3027| codons 1-99 PQITLWQRPIVTIKIGGQLKEALLDTGADDTVLEEMNLPGRWKPKLIVGIGGFVKVREYD QICIEICGHKVIGTVLIGPTPANIIGRNLLTKLGCTLNF |
References
| Author | Title | Citation |
| Shulman, NS | Efavirenz- and adefovir dipivoxil-based salvage therapy in highly treatment-experienced patients: clinical and genotypic predictors of virologic response. | JAIDS, 2000 |
| Gonzales, MJ | HIV-1 reverse transcriptase and protease subtypes: classification, amino acid mutation patterns, and prevalence in a Northern California clinic-based population. | J Infect Dis, 2001 |
| Gonzales, MJ | Extended spectrum of HIV-1 reverse transcriptase mutations in patients receiving multiple nucleoside analog inhibitors. | AIDS, 2003 |
| Gonzales, MJ | Protease and reverse transcriptase mutation patterns in HIV-1 isolates from heavily treated persons: comparison of isolates from northern California with isolates from other regions. | ARHR, 2003 |
| Rhee, SY | HIV-1 Protease and Reverse Transcriptase Mutations: Correlations with Antiretroviral Therapy in Subtype B Isolates and Implications for Drug-Resistance Surveillance. | J Infect Dis, 2005 |